Journal Title：European Journal Of Clinical Pharmacology

The European Journal of Clinical Pharmacology publishes original papers on all aspects of clinical pharmacology and drug therapy in humans. Manuscripts are welcomed on the following topics: therapeutic trials, pharmacokinetics/pharmacodynamics, pharmacogenetics, drug metabolism, adverse drug reactions, drug interactions, all aspects of drug development, development relating to teaching in clinical pharmacology, pharmacoepidemiology, and matters relating to the rational prescribing and safe use of drugs. Methodological contributions relevant to these topics are also welcomed.

Data from animal experiments are accepted only in the context of original data in man reported in the same paper. EJCP will only consider manuscripts describing the frequency of allelic variants in different populations if this information is linked to functional data or new interesting variants. Highly relevant differences in frequency with a major impact in drug therapy for the respective population may be submitted as a letter to the editor.

Straightforward phase I pharmacokinetic or pharmacodynamic studies as parts of new drug development will only be considered for publication if the paper involves

-a compound that is interesting and new in some basic or fundamental way, or

-methods that are original in some basic sense, or

-a highly unexpected outcome, or

-conclusions that are scientifically novel in some basic or fundamental sense.

《歐洲臨床藥理學雜志》發表關于人類臨床藥理學和藥物治療各個方面的原創論文。歡迎投稿，主題包括：治療試驗、藥代動力學/藥效學、藥物遺傳學、藥物代謝、藥物不良反應、藥物相互作用、藥物開發的各個方面、與臨床藥理學教學相關的發展、藥物流行病學以及與合理處方和安全用藥相關的事項。也歡迎與這些主題相關的方法學貢獻。

動物實驗數據僅在同一篇論文中報告的人類原始數據背景下才被接受。EJCP 僅會考慮描述不同人群等位基因變異頻率的稿件，前提是這些信息與功能數據或新的有趣變異相關。頻率高度相關的差異，對相應人群的藥物治療有重大影響，可以以致編輯信的形式提交。

作為新藥開發的一部分，簡單的 I 期藥代動力學或藥效學研究僅在論文涉及以下方面時才會被考慮發表：

- 某種化合物在某些基本或根本方面有趣且新穎，或

- 某種方法在某些基本意義上是原創的，或

- 非常出乎意料的結果，或

- 結論在某些基本或根本意義上具有科學上的新穎性。

European Journal Of Clinical Pharmacology創刊于1968年，由Springer Berlin Heidelberg出版商出版，收稿方向涵蓋醫學 - 藥學全領域，此刊是中等級別的SCI期刊，所以過審相對來講不是特別難，但是該刊專業認可度不錯，仍然是一本值得選擇的SCI期刊 。平均審稿速度 一般,3-8周 ，影響因子指數2.4，該期刊近期沒有被列入國際期刊預警名單，廣大學者值得一試。